Skip to main content
Beijing Konruns Pharmaceutical Co.,Ltd. logo

Beijing Konruns Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 603590 ISIN · CNE1000036K3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,201 across all filing types
Latest filing 2026-05-15 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603590

About Beijing Konruns Pharmaceutical Co.,Ltd.

https://www.konruns.cn/

Beijing Konruns Pharmaceutical Co., Ltd. focuses on the research, development, and commercialization of innovative therapeutic solutions. The company specializes in surgical hemostasis and oncology. Its flagship product, Suling (Hemocoagulase Agkistrodon for Injection), is a proprietary hemostatic agent derived from snake venom, utilized in clinical surgical procedures to control bleeding. Konruns maintains an R&D pipeline centered on targeted cancer therapies, including KC1036, a multi-target kinase inhibitor for solid tumors. The organization integrates drug discovery, clinical development, and manufacturing processes to address unmet medical needs in hematology and metabolic diseases. Its strategic focus remains on high-value clinical innovation and the advancement of proprietary chemical and biological drug candidates.

Recent filings

Filing Released Lang Actions
康辰药业关于使用部分闲置募集资金进行现金管理赎回的公告
Capital/Financing Update Classification · 85% confidence The document is an official exchange disclosure by Beijing Kangchen Pharmaceutical Co., Ltd. detailing the redemption of cash management products purchased with idle proceeds from prior fundraising. It is not a full financial report or an earnings release, nor is it an AGM or annual report. Instead, it provides an update on the use and management of financing proceeds. This clearly fits the Capital/Financing Update category.
2026-05-15 Chinese
康辰药业关于股份回购进展公告
Transaction in Own Shares Classification · 100% confidence The document is a public announcement from Beijing Kangchen Pharmaceutical Co., Ltd. regarding the progress of its share repurchase program. It details the number of shares repurchased, the price range, total amount spent, and the purpose of the repurchase (employee stock ownership plan or equity incentives). The document references the initial repurchase plan disclosed on 2025/10/16 and provides an update on the repurchase progress as of 2026/4/30. The content is focused on the company's own shares buyback activity and does not contain financial statements or earnings data. The document length is short (1150 characters) and it is clearly an announcement of share repurchase progress, fitting the category of Transaction in Own Shares (POS).
2026-05-07 Chinese
康辰药业2025年年度股东会会议资料
AGM Information Classification · 100% confidence The document is titled as materials for the 2025 Annual General Meeting (AGM) of Beijing Kangchen Pharmaceutical Co., Ltd. It contains detailed agenda items, meeting instructions, and multiple proposals to be discussed and voted on during the AGM, including the 2025 Board of Directors work report, profit distribution plan, amendments to remuneration policies, appointment of auditors, and stock repurchase plans. It also includes reports to be heard such as independent directors' reports and senior management remuneration execution. The document is structured as meeting materials rather than a full annual report or financial statement. It is not a brief announcement or a certification but a comprehensive set of AGM meeting documents. Therefore, it fits the category of AGM Information (AGM-R).
2026-05-07 Chinese
康辰药业第五届董事会第二次会议决议公告
Regulatory Filings Classification · 80% confidence The document is an official disclosure announcing the resolutions of the company’s fifth board meeting (Board Meeting minutes) covering items such as approval of the 2025 annual report, profit distribution plan, remuneration proposals, audit firm appointments, funding usage reports, etc. It does not itself change board composition (so not MANG), nor is it a full report (10-K, IR), proxy materials, earnings release, or other specialized filings. It is a standard board resolution announcement under continuous disclosure obligations, fitting the fallback category for general regulatory announcements (RNS).
2026-04-22 Chinese
北京康辰药业股份有限公司对华兴会计师事务所（特殊普通合伙）履职情况评估的报告
Regulatory Filings Classification · 60% confidence The document is an in‐depth evaluation by a listed company of the performance of its external auditor during the 2025 audit engagement. It is not the auditor’s own audit report (no audit opinion on financial statements), nor is it an annual or interim financial report, earnings release, management discussion, or any other defined category. It doesn’t announce the publication of another report but instead provides substantive content on auditor evaluation. Therefore it falls into the general fallback category for miscellaneous regulatory filings.
2026-04-22 Chinese
康辰药业2025年年度利润分配方案公告
Notice of Dividend Amount Classification · 93% confidence The document is titled “2025年年度利润分配方案公告” and provides detailed information on per-share cash dividends, the base share count, total cash dividend amount, record date mechanics, board approval, and related risk disclosures. This is a classic dividend distribution plan announcement specifying dividend ratios and total payout. Therefore, it falls under “Notice of Dividend Amount” (DIV).
2026-04-22 Chinese

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.